Boston Scientific Corporation has seen a robust rally from several rounds of positive news. Wall Street analysts have been showing bullish views and have raised target prices on Boston Scientific’s shares, with
RBC Capital and Truist among the bullish entities. Notably,
Jim Cramer dubbed Boston Scientific as one of the most reliable companies. In Q2 2025, Boston Scientific
surpassed estimates on earnings and sales, leading to a lifting of its annual profit forecast. Additionally, this promising performance prompted a stock upgrade, and it continued to outpace its Medical peers. However, Boston Scientific insiders sold around $2.3 million of stock, potentially indicating a future weakness. Further, Boston Scientific received
FDA approval for expanded labeling of its
FARAPULSE Pulsed Field Ablation system, indicating a progression in its innovation in medical techniques. Still, some market participants remain uncertain about Boston Scientific's fundamentals, despite its vigorous stock performance. The company also recently completed a €1.5 billion sale of senior notes, potentially providing additional funds to fuel its growth.
Boston Scientific Corp BSX News Analytics from Wed, 15 Jan 2025 08:00:00 GMT to Sat, 02 Aug 2025 12:16:56 GMT -
